Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin
(mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel
with carboplatin should lead to improvements in efficacy as measured by progression-free
survival and response rate.